Julianne Averill - Net Worth and Insider Trading

Julianne Averill Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Julianne Averill owns 1 companies in total, including Armata Pharmaceuticals Inc (ARMP) .

Click here to see the complete history of Julianne Averill’s form 4 insider trades.

Insider Ownership Summary of Julianne Averill

Ticker Comapny Transaction Date Type of Owner
ARMP Armata Pharmaceuticals Inc 2023-05-02 Chief Financial Officer

Julianne Averill Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Julianne Averill Ownership Network

Ownership Network List of Julianne Averill

No Data

Ownership Network Relation of Julianne Averill


Julianne Averill Owned Company Details

What does Armata Pharmaceuticals Inc do?

Who are the key executives at Armata Pharmaceuticals Inc?

Julianne Averill is the Chief Financial Officer of Armata Pharmaceuticals Inc. Other key executives at Armata Pharmaceuticals Inc include Corporate Controller and PFO Richard Rychlik , director & Chief Executive Officer Deborah Birx , and Vice President,Finance & Admin Erin Butler .

Armata Pharmaceuticals Inc (ARMP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Armata Pharmaceuticals Inc (ARMP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Armata Pharmaceuticals Inc (ARMP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Armata Pharmaceuticals Inc (ARMP)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Armata Pharmaceuticals Inc Insider Transactions

No Available Data

Julianne Averill Mailing Address

Above is the net worth, insider trading, and ownership report for Julianne Averill. You might contact Julianne Averill via mailing address: 361 Newbury Street, Suite 500, Boston Ma 02115.

Discussions on Julianne Averill

No discussions yet.